Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report

von Seidlein, Lorenz, Auburn, Sarah, Espino, Fe, Shanks, Dennis, Cheng, Qin, McCarthy, James, Baird, Kevin, Moyes, Catherine, Howes, Rosalind, Menard, Didier, Bancone, Germana, Winasti-Satyahraha, Ari, Vestergaard, Lasse S., Green, Justin, Domingo, Gonzalo, Yeung, Shunmay and Price, Ric (2013) Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malaria Journal, 12 1: 112.1-112.12. doi:10.1186/1475-2875-12-112


Author von Seidlein, Lorenz
Auburn, Sarah
Espino, Fe
Shanks, Dennis
Cheng, Qin
McCarthy, James
Baird, Kevin
Moyes, Catherine
Howes, Rosalind
Menard, Didier
Bancone, Germana
Winasti-Satyahraha, Ari
Vestergaard, Lasse S.
Green, Justin
Domingo, Gonzalo
Yeung, Shunmay
Price, Ric
Title Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report
Journal name Malaria Journal   Check publisher's open access policy
ISSN 1475-2875
Publication date 2013-03
Year available 2013
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1186/1475-2875-12-112
Open Access Status DOI
Volume 12
Issue 1
Start page 112.1
End page 112.12
Total pages 12
Place of publication London, United Kingdom
Publisher BioMed Central
Collection year 2014
Language eng
Formatted abstract
The diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency is a crucial aspect in the current phases of malaria control and elimination, which will require the wider use of 8-aminoquinolines for both reducing Plasmodium falciparum transmission and achieving the radical cure of Plasmodium vivax. 8-aminoquinolines, such as primaquine, can induce severe haemolysis in G6PD-deficient individuals, potentially creating significant morbidity and undermining confidence in 8-aminoquinoline prescription. On the other hand, erring on the side of safety and excluding large numbers of people with unconfirmed G6PD deficiency from treatment with 8-aminoquinolines will diminish the impact of these drugs. Estimating the remaining G6PD enzyme activity is the most direct, accessible, and reliable assessment of the phenotype and remains the gold standard for the diagnosis of patients who could be harmed by the administration of primaquine. Genotyping seems an unambiguous technique, but its use is limited by cost and the large range of recognized G6PD genotypes. A number of enzyme activity assays diagnose G6PD deficiency, but they require a cold chain, specialized equipment, and laboratory skills. These assays are impractical for care delivery where most patients with malaria live. Improvements to the diagnosis of G6PD deficiency are required for the broader and safer use of 8-aminoquinolines to kill hypnozoites, while lower doses of primaquine may be safely used to kill gametocytes without testing. The discussions and conclusions of a workshop conducted in Incheon, Korea in May 2012 to review key knowledge gaps in G6PD deficiency are reported here
Keyword Malaria
Vivax
Falciparum
Primaquine
Tafenoquine
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2014 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 43 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 42 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 12 May 2013, 00:56:31 EST by System User on behalf of Medicine - Royal Brisbane and Women's Hospital